The filing of a new international patent application by RenovoRx is likely to be viewed positively by investors as it suggests potential for future growth and market expansion. The expansion of the TAMP platform to include a wider range of therapies could make the company's technology more versatile and valuable. The ongoing Phase III clinical trial adds credibility to the platform's efficacy and could lead to increased investor confidence if results are favorable. However, the actual impact on the stock will depend on the market's perception of the patent's potential value and the progress of the clinical trials.